Athenex, Inc. Announces Third Quarter 2018 Financial Results and Provides Corporate Update
Third quarter revenue increased to $18.4 million compared to $14.0 million in 3Q 2017 Positive recommendation by DSMB upon second interim analysis for Oraxol Phase III program KX2-391 Phase III pivotal studies achieved primary endpoints Oratecan and …